Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.
Yildirim HC, Kapar C, Koksal B, Seyyar M, Sanci PC, Guliyev M, Perkin P, Buyukkor M, Yaslikaya S, Majidova N, Keskinkilic M, Ozaskin D, Avci T, Gunes TK, Arcagok M, Topal A, Keskin GSY, Kavgaci G, Yildirim N, Celayir OM, Avci N, Aslan F, Alkan A, Erciyestepe M, Cengiz M, Pehlivan M, Gulmez A, Beypinar I, Basoglu Tuylu T, Kayikcioglu E, Chalabiyev E, Turhal S, Guzel HG, Ayas E, Sahbazlar M, Dulgar O, Demir H, Yavuzsen T, Bayoglu V, Kivrak Salim D, Ozturk B, Ozdemir F, Kara O, Oksuzoglu B, Bal O, Demirci NS, Yilmaz M, Cabuk D, Aksoy S. Yildirim HC, et al. Among authors: keskinkilic m. J Chemother. 2024 Mar 18:1-7. doi: 10.1080/1120009X.2024.2330835. Online ahead of print. J Chemother. 2024. PMID: 38497444
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Yıldırım HÇ, Kutlu Y, Mutlu E, Aykan MB, Korkmaz M, Yalçın S, Şakalar T, Celayir ÖM, Kayıkçıoğlu E, Aslan F, Hafızoğlu E, Altıntaş YE, Keskinkılıç M, Chalabiyev E, Çelebi A, Dursun B, Kapar C, Özen M, Acar Ö, Dülgar Ö, Kut E, Biter S, Kus F, Almuradova E, Erdoğan AP, Saray S, Güven DC, Şimşek ET, Üskent N, Kemal Y, Çakar B, Açıkgöz Ö, Kılıçkap S, Aksoy S. Yıldırım HÇ, et al. Among authors: keskinkilic m. Int J Clin Oncol. 2024 Mar;29(3):258-265. doi: 10.1007/s10147-023-02460-5. Epub 2024 Feb 4. Int J Clin Oncol. 2024. PMID: 38310597
Triple Negative Breast Cancers: An Obsolete Entity?
Keskinkılıc M, Gökmen-Polar Y, Badve SS. Keskinkılıc M, et al. Clin Breast Cancer. 2024 Jan;24(1):1-6. doi: 10.1016/j.clbc.2023.10.006. Epub 2023 Oct 31. Clin Breast Cancer. 2024. PMID: 38016912 Review.
The role of immune checkpoint inhibition in triple negative breast cancer.
Tarekegn K, Keskinkilic M, Kristoff TJ, Evans ST, Kalinsky K. Tarekegn K, et al. Among authors: keskinkilic m. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1095-1106. doi: 10.1080/14737140.2023.2265059. Epub 2023 Oct 26. Expert Rev Anticancer Ther. 2023. PMID: 37771270 Review.
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study.
Caliskan Yildirim E, Atag E, Coban E, Umit Unal O, Celebi A, Keser M, Uzun M, Keskinkilic M, Tanrikulu Simsek E, Sari M, Yavuzsen T. Caliskan Yildirim E, et al. Among authors: keskinkilic m. Breast. 2023 Aug;70:56-62. doi: 10.1016/j.breast.2023.06.006. Epub 2023 Jun 14. Breast. 2023. PMID: 37343321 Free PMC article.
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Sakach E, Keskinkilic M, Wood S, Canning M, Kalinsky K. Sakach E, et al. Among authors: keskinkilic m. Curr Treat Options Oncol. 2023 Sep;24(9):1103-1119. doi: 10.1007/s11864-023-01109-9. Epub 2023 Jun 14. Curr Treat Options Oncol. 2023. PMID: 37314645 Review.
17 results